Tirzepatide vs Semaglutide: Which Is Better for Weight Loss? BioHarmony head-to-head comparison
Head-to-Head Comparison

Tirzepatide vs Semaglutide: Which Is Better for Weight Loss?

Should I take tirzepatide or semaglutide?

Reviewed 09/07/2026

Tirzepatide scores 6.1 and semaglutide 6.0, so the overall scores don't pick a winner. Your reason for taking one does. Tirzepatide wins on weight and body composition. Semaglutide wins when you need proven cardiovascular or kidney outcome data, and it costs about $100 a month less at maintenance.

  • Tirzepatide 6.1, semaglutide 6.0. A 0.1 gap is not a recommendation, so read the use-case rows instead.
  • Tirzepatide hits both the GIP and the GLP-1 receptor. Semaglutide hits GLP-1 only. That second receptor is where the extra weight loss comes from.
  • Semaglutide is the only one of the two with a completed outcome trial in obesity without diabetes (SELECT) and in diabetic kidney disease (FLOW).
  • Self-pay estimates put semaglutide at $199 to $349 a month and tirzepatide at $299 to $449. Both are estimates from manufacturer direct programs, not measured retail.
  • Both regain weight after you stop. Randomized withdrawal data says so on each side, so plan for chronic therapy or don't start.
  • Neither protects muscle. Resistance training and protein aren't optional add-ons here, they're part of the dose.

At a Glance

Tirzepatide
Option A

Tirzepatide

6.1 / 10 Worth trying
Upside
  • Efficacy 5.0
  • Breadth 4.8
  • Evidence 4.4
  • Speed 4.2
  • Durability 2.0
  • Bioindividuality 4.4
Downside
  • Safety Risk 4.0
  • Side Effects 2.4
  • Cost 2.2
  • Effort 1.6
  • Opportunity Cost 2.1
  • Dependency 3.5
  • Reversibility 1.7
Best at:
  • Blood Sugar 9.2
  • Body Composition 9.0
  • Metabolic Health 8.7
  • Liver Detox 8.3

Dual GIP and GLP-1 receptor agonist. BioHarmony 6.1, worth trying.

Read full BioHarmony report →

Semaglutide
Option B

Semaglutide

6.0 / 10 Worth trying
Upside
  • Efficacy 4.8
  • Breadth 4.8
  • Evidence 4.4
  • Speed 3.8
  • Durability 2.0
  • Bioindividuality 4.3
Downside
  • Safety Risk 4.0
  • Side Effects 2.5
  • Cost 2.1
  • Effort 1.5
  • Opportunity Cost 2.2
  • Dependency 3.5
  • Reversibility 1.7
Best at:
  • Blood Sugar 9.5
  • Metabolic Health 9.0
  • Cardiovascular 8.0
  • Liver Detox 7.5

Single GLP-1 receptor agonist. BioHarmony 6.0, worth trying.

Read full BioHarmony report →

Head-to-Head Verdict

Use CaseWinnerRationale
Body CompositionTirzepatideTirzepatide subrating 9.0 against semaglutide's 7.0, and the one direct randomized comparison we hold backs it up: SURPASS-2 (Frias 2021) gave tirzepatide greater body-weight reduction than semaglutide 1 mg in type 2 diabetes. If pounds are the endpoint, this is the row that decides it.
Blood SugarTieCall this even. SURPASS-2 gave tirzepatide the HbA1c edge, but the comparator was semaglutide 1 mg, not the 2.4 mg dose most people now use. The subratings land 9.5 semaglutide against 9.2 tirzepatide. Both are at the top of what any glucose-lowering drug does.
CardiovascularSemaglutideSemaglutide 8.0 against tirzepatide 7.8, and the gap is about trial design. SELECT (Lincoff 2023) showed 20% lower 3-point MACE in adults with overweight or obesity and established cardiovascular disease without diabetes. Tirzepatide's cardiovascular outcome data (Nicholls 2025) is against dulaglutide in type 2 diabetes, which is a different question.
Kidney FunctionSemaglutideSemaglutide 7.0 against tirzepatide 5.8. FLOW (Perkovic 2024) reported 24% lower risk of the major kidney disease or death composite in type 2 diabetes plus chronic kidney disease. Tirzepatide has no equivalent renal outcome trial, and its own report flags dehydration-driven kidney risk during severe GI reactions.
Sleep QualityTirzepatideTirzepatide 8.0 against semaglutide 6.0, the widest gap in the matrix. The tirzepatide report positions obesity-related obstructive sleep apnea as an adjunctive indication in its own right. That's a specific clinical use, not a general "you'll sleep better because you lost weight" claim.
RespiratoryTirzepatideTirzepatide 7.5 against semaglutide 5.5, driven by the same sleep-apnea and HFpEF signal. Packer 2025 showed reduced worsening heart-failure events and improved health status in HFpEF with obesity, which is where breathlessness actually lives for this population.
Liver DetoxTieThe subratings say tirzepatide 8.3 against semaglutide 7.5, but the trial phases say the opposite. Loomba 2024 is a phase 2 readout for tirzepatide in MASH with fibrosis. Sanyal 2025 is a phase 3 interim for semaglutide with both resolution and fibrosis endpoints. Weight the effect size and tirzepatide leads. Weight the evidence tier and semaglutide does.
HealthspanSemaglutideSemaglutide 7.5 against tirzepatide 7.0. Semaglutide is the one with hard outcome wins across three organ systems: cardiovascular (SELECT), kidney (FLOW) and liver (Sanyal 2025). Healthspan means events avoided, and that's the column semaglutide currently fills.
Muscle GrowthTieTirzepatide 2.5, semaglutide 3.0. Both are near the bottom of the scale and neither is a reason to pick one. Rapid loss costs lean mass on either drug, which is why both source reports put resistance training and protein intake inside the protocol rather than beside it.

Cost Comparison

InterventionMonthly CostNotes
Tirzepatide$299 to $449ESTIMATE, priced 2026-09-07, telehealth and manufacturer self-pay channel. LillyDirect self-pay Zepbound vials run $299 per 28 days at 2.5 mg, $399 at 5 mg and $449 at 7.5 through 15 mg, which covers the whole standard titration. Branded pharmacy retail without coverage is far higher. This is a channel estimate, not a measured price you're guaranteed to pay.
Semaglutide$199 to $349ESTIMATE, priced 2026-09-07, telehealth and manufacturer self-pay channel. NovoCare Pharmacy self-pay Wegovy is $199 per month for the first two fills at 0.25 to 0.5 mg and $349 per month afterward across every dose in the titration. Branded cash retail is $1,000 to $1,350. Again an estimate from the direct program, not a measured retail figure.
The differenceAbout $100 a month at maintenanceAt maintenance you're comparing $449 against $349, so roughly $1,200 a year. That's the clearest reason to start on semaglutide when your use case is otherwise a tie.It stops deciding things when body composition is the goal, because tirzepatide's edge there is worth paying for. Both figures assume the manufacturer's direct program. Branded retail without coverage changes the comparison completely.

When to Switch

Both drugs change appetite inside about a week, so early feel tells you almost nothing. The number that matters is the 16-week assessment window, which is the same on both. Judge at 16 weeks, not at 4.

Move from semaglutide to tirzepatide when body composition has plateaued at the 2.4 mg maintenance dose through a full window, with protein and resistance training already in place: tirzepatide reaches full effect around week 20 against semaglutide's 48. Do not switch for a cardiovascular or kidney reason, because those are the two places semaglutide holds outcome data tirzepatide doesn't. Move the other way, from tirzepatide to semaglutide, for cost (about $100 a month), for GI intolerance you can't titrate around, or when established cardiovascular disease or diabetic kidney disease enters the picture.

Either direction, don't overlap them. Both act through GLP-1, so running them together multiplies the GI burden with no mechanism story behind it. Stop one, start the other at its lowest titration step, and expect to re-climb the ladder.

Who Should Pick What?

Adult with a BMI over 35 whose main goal is losing weight

Tirzepatide

Body-composition subrating 9.0 against 7.0, and SURPASS-2 is the direct randomized comparison backing it. You're paying about $100 more a month for the biggest single advantage in this comparison.

Adult with obesity and established cardiovascular disease, no diabetes

Semaglutide

This is the exact SELECT population, and SELECT is the trial that showed 20% lower 3-point MACE. Tirzepatide has nothing equivalent in this group. Fewer pounds is not worth trading away a proven event reduction.

Type 2 diabetic with chronic kidney disease

Semaglutide

FLOW showed a 24% lower major kidney disease or death composite in exactly this group. Tirzepatide's kidney subrating is 5.8 and its own report flags dehydration risk during severe GI reactions, which is the wrong direction for a compromised kidney.

Adult with obesity and diagnosed obstructive sleep apnea

Tirzepatide

Sleep-quality subrating 8.0 against 6.0 and respiratory 7.5 against 5.5. The tirzepatide report treats OSA as an adjunctive indication. Keep using your PAP machine until a repeat sleep study says otherwise.

Cost is the binding constraint and your use case is otherwise a tie

Semaglutide

$199 to $349 against $299 to $449 through the manufacturers' direct programs, so about $1,200 a year. When the matrix rows relevant to you come out even, price is a legitimate tie-breaker.

Metabolically healthy and after a cosmetic 10 pounds

Tie

Neither. Both source reports say the risk-benefit stops working without real metabolic pathology, and both carry a thyroid C-cell boxed warning, pregnancy restrictions and a chronic-therapy commitment. This is the row where the honest answer is to not start.

Planning a pregnancy in the next year

Tie

Neither, for now. Pregnancy or planned conception is a listed contraindication on both, and both need a washout plan built with a clinician before you try to conceive.

Research Highlights

  1. Mechanism Difference

    Semaglutide activates one receptor. Tirzepatide activates two. Semaglutide is a GLP-1 agonist: it raises glucose-dependent insulin secretion, lowers glucagon, slows gastric emptying and suppresses appetite.Tirzepatide does all of that and adds GIP receptor agonism, which brings further appetite suppression and adipose insulin sensitisation. That second receptor is why its body-composition subrating is 9.0 against semaglutide's 7.0, and why SURPASS-2 (Frias 2021) favored it on weight.

  2. Safety Comparison

    Neither drug wins on safety. Both carry the same thyroid C-cell boxed-warning context, the same medullary thyroid carcinoma and MEN2 contraindications, pregnancy restrictions, pancreatitis and gallbladder warnings, and the same aspiration concern around anesthesia.Both score 4.0 on safety risk and sit within 0.1 on side-effect profile. Two differences matter: semaglutide adds a retinopathy caution and a reported NAION signal (Hathaway 2024), tirzepatide adds dehydration-driven kidney risk during severe GI reactions.

  3. Cost Comparison

    Through the manufacturers' direct self-pay programs, semaglutide runs about $199 to $349 a month and tirzepatide about $299 to $449, both priced 2026-09-07. At maintenance that's $349 against $449, so roughly $1,200 a year. Both are channel estimates, not measured retail: branded cash retail for semaglutide is $1,000 to $1,350. Benefit here is chronic, so plan against the multi-year figure.

  4. Editorial Verdict

    Tirzepatide scores 6.1 and semaglutide 6.0, a gap too small to act on, so the decision is use-case driven. Take tirzepatide when body composition, sleep apnea or obesity-related heart failure is the target: its subratings there run 1.5 to 2.0 points higher.Take semaglutide when you need an outcome trial behind the call (SELECT, FLOW, Sanyal 2025), or when the $100 a month matters. Both regain weight after you stop and neither protects lean mass.

  5. Durability

    Neither drug's benefit survives stopping it. Aronne 2023 showed continued tirzepatide maintained weight reduction while a switch to placebo led to regain. Rubino 2021 (STEP-4) showed the same for semaglutide. Both score 2.0 out of 5.0 on durability. Treat either as chronic therapy with an exit plan.

Frequently Asked Questions

Is tirzepatide better than semaglutide?
For weight, yes. Tirzepatide's body-composition subrating is 9.0 against semaglutide's 7.0, and SURPASS-2 showed greater weight reduction with tirzepatide than semaglutide 1 mg. Overall the scores are 6.1 and 6.0, a tie in practice. Semaglutide wins if you need cardiovascular (SELECT) or kidney (FLOW) outcome data, and it's about $100 a month cheaper.
Why does tirzepatide cause more weight loss than semaglutide?
Tirzepatide activates the GIP receptor as well as the GLP-1 receptor. Semaglutide only activates GLP-1. The extra GIP arm adds appetite suppression and adipose insulin sensitisation on top of the shared GLP-1 effects, which are glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying and hypothalamic satiety signaling.
Which one is cheaper, tirzepatide or semaglutide?
Semaglutide, by about $100 a month. NovoCare Pharmacy self-pay is roughly $199 for the first two fills and $349 after that. LillyDirect self-pay tirzepatide vials run $299 to $449 by dose. Both are estimates priced 2026-09-07 from manufacturer programs, not measured retail. Branded cash retail runs far higher, up to $1,350 a month for semaglutide.
How long before I know if it's working?
Both drugs give a first noticeable appetite change in about a week, but the assessment window on each is 16 weeks. Judge at 16 weeks. Full effect lands around week 20 for tirzepatide and week 48 for semaglutide, so semaglutide keeps improving for longer after that first assessment.
Can I switch from semaglutide to tirzepatide?
Yes, with a prescriber. The trigger is a body-composition plateau at the 2.4 mg semaglutide maintenance dose after a full 16-week window, with protein and resistance training already handled. Don't overlap them: stop one, start the other at its lowest step. Don't switch away if cardiovascular or kidney risk is why you're on semaglutide.
Do I regain the weight if I stop?
On both, usually. SURMOUNT-4 (Aronne 2023) showed regain after switching tirzepatide to placebo, and STEP-4 (Rubino 2021) showed the same for semaglutide. Both score 2.0 out of 5.0 on durability. Plan for chronic therapy with an exit strategy rather than a fixed course.
Who should not take either one?
Anyone with a personal or family history of medullary thyroid carcinoma or MEN2, anyone pregnant or planning conception, and anyone with a pancreatitis history, severe gastroparesis, gallbladder disease, or upcoming anesthesia without a fasting plan.Semaglutide adds a proliferative diabetic retinopathy caution. Tirzepatide adds dehydration-driven kidney risk. Neither fits a metabolically healthy person chasing a cosmetic result.
Will I lose muscle on either drug?
Some, on both. Tirzepatide's muscle-growth subrating is 2.5 and semaglutide's is 3.0, so neither protects lean mass. Rapid loss costs muscle and bone. Progressive resistance training and hitting a protein target despite low appetite are part of the protocol on either drug, not optional extras.

Evidence Sources

Glossary

Quick reference for the medical and technical terms used in this comparison.

GLP-1 Glucagon-Like Peptide-1
A gut hormone that tells the pancreas to release insulin when glucose is high, slows stomach emptying and reduces appetite. Both drugs act on its receptor.
GIP Glucose-Dependent Insulinotropic Polypeptide
A second gut hormone. Tirzepatide hits this receptor as well as GLP-1, semaglutide doesn't. It's the mechanistic difference between the two drugs.
MACE Major Adverse Cardiovascular Events
The standard composite endpoint in heart trials: cardiovascular death, non-fatal heart attack, non-fatal stroke. SELECT cut 3-point MACE by 20% on semaglutide.
HbA1c Glycated Hemoglobin
A 2 to 3 month average of blood glucose. The primary endpoint in most diabetes trials, including SURPASS-2.
MASH Metabolic Dysfunction-Associated Steatohepatitis
Fatty liver disease with inflammation and liver-cell damage. Formerly called NASH. Both drugs have trial data here, at different phases.
MTC Medullary Thyroid Carcinoma
The rare thyroid cancer named in both drugs' boxed warnings. A personal or family history of it rules out both.
MEN2 Multiple Endocrine Neoplasia type 2
A hereditary syndrome that raises MTC risk. A hard contraindication for both drugs.
HFpEF Heart Failure with Preserved Ejection Fraction
Heart failure where the heart pumps normally but doesn't fill properly. Tirzepatide has a dedicated trial here (Packer 2025).
NAION Nonarteritic Anterior Ischemic Optic Neuropathy
Sudden vision loss from reduced blood flow to the optic nerve. A reported semaglutide-specific safety signal (Hathaway 2024).
Nick Urban

Health Optimization Researcher & CHEK Holistic Lifestyle Coach Level 2

I've spent over a decade testing metabolic interventions on myself and screening them for clients and podcast guests

Reviewed Sep 7, 2026 · next review Dec 6, 2026

Find which one fits your biology

Take the BioHarmony Quiz